A new dedicated phase I clinical trials unit at Hollings means more and different types of clinical trials will be available to cancer patients.

A new study is the first in the U.S. to show that an available generic drug could help people stop using e-cigarettes.

MUSC’s pipeline programs build the skills of underrepresented students and prepare them for careers in health care and medical research.

A recent MUSC study found that hypertensive disorders of pregnancy may contribute to higher rates of blood clots in women years after delivery.

For people with HIV, the risk of anal cancer varies significantly depending on the region of the country where they live.

MUSC’s ReJoyce Green, Ph.D., leads study highlighted in prestigious publication showing which factors may predict substance use in adolescents.

After melanoma surgery, hairdresser Carol Helton is spreading the word at her hair salon about staying on top of suspicious moles.

A clinical trial of CAR-T cell therapy developed at Hollings has received NCI funding to expand.

An Ewing sarcoma researcher at MUSC is one of three scientists nationwide to receive a career development award from the Rally Foundation.

Teams working to improve substance use screening in trauma centers and relieve symptoms of a connective tissue disease take home this year’s Blue Sky Awards.